131I-TLX-101 for Treatment of Newly Diagnosed Glioblastoma (IPAX-2)

Clinical trial NCT05450744 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT05450744
Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Neoplastic Disease Glioblastoma Glioblastoma Multiforme

Start date: 2023-04-01
Primary completion: 2027-06-01
Enrollment: 12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.